Aspira Womens Health Inc (VRML)

HEALTH CARE: HEALTH CARE SERVICES
SIC: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES

12117 BEE CAVES ROAD BUILDING THREE AUSTIN, TX 78738

Vermillion is involved in the discovery, development and commercialization of specialty diagnostic tests that provide physicians with information, with which to manage their patients' care and that improve patient outcomes. The company intends to do this using translational proteomics, which is the process of answering clinical questions by utilizing protein separation tools to identify and resolve variants of specific biomarkers, developing assays and commercializing tests. Specifically, the clinical questions addressed by the company include early disease detection, treatment response, monitoring of disease progression, prognosis and others.

Data as of 2020-09-12
Market Cap297.964 Million Shares Outstanding103.82 Million Avg 30-day Volume772.936 Thousand
P/E Ratio Dividend Yield EPS-0.16
Price/Sales65.357 Price cash flow ratio Price free cash flow ratio-23.7
Book Value0.07 Price to Tangible Book43.72 Alpha0.01
Short Interest Ratio % Short Interest to Float R-squared0.164438
BETA3.26259 52-week High/Low5.78 / 0.3506 Stddev0.343771

Are you looking for this stock instead?

View SEC Filings from VRML instead.
Q2 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 2 2 0.0% 2 (0.13%) 2 (0.13%) 0.0%
Funds Holding: 62 33 87.88% 13 (0.85%) 11 (0.7%) 18.18%
13F shares: 23.808 Million 17.594 Million 35.32% 15.339 Million 13.608 Million 12.72%
% Ownership 22.9637 18.0676 27.1% 14.7948 13.9741 5.87%
New Positions: 37 6 516.67% 6 1 500.0%
Increased Positions 15 9 66.67% 5 1 400.0%
Closed Positions 6 5 20.0% 3 4 -25.0%
Reduced Positions 4 4 0.0% 1 3 -66.67%
Total Calls 435.365 Thousand 0 15.5 Thousand
Total Puts 753 0
PUT/CALL Ratio 0.0 0.0
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding VRML (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding VRML BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

50 Thousand total shares from 1 transactions

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SCHREIBER DAVID

  • Director
185,018 2020-09-08 2

FEINBERG LARRY N

ORACLE PARTNERS LP

  • SHAREHOLDERSHAREHOLDER
10,288,587 2020-07-09 2

SCHULER JACK W

25,394,517 2020-07-01 2

BURNS JAMES S

  • Director
473,461 2020-06-05 2

PALMIERI VALERIE BARBER PRESIDENT AND CEO

  • Officer
  • Director
223,094 2020-06-05 3

JORDAN VERONICA GH

  • Director
288,694 2020-06-05 2

LAFRANCE JAMES T

  • Director
434,480 2020-06-02 3

BEECHEY ROBERT HARRY CHIEF FINANCIAL OFFICER

  • Officer
0 2020-06-01 3

COCOZZA NANCY G

  • Director
129,506 2020-03-19 2

SCHULER HENRI GEORGE

13,764,495 2019-06-28 0

PALMIERI VALERIE BARBER PRESIDENT AND CEO

PALMIERI VALERIE BARBER PRESIDENT AND CEO

  • Officer
  • Director
0 2019-03-26 3

SEVERINGHAUS CARL

  • Director
282,296 2018-04-13 0

FERRARA FRED CHIEF OPERATING OFFICER

  • Officer
0 2018-04-13 0

FEINBERG LARRY N

ORACLE PARTNERS LP

ORACLE TEN FUND MASTER, LP

ORACLE INSTITUTIONAL PARTNERS L P

ORACLE ASSOCIATES LLC

ORACLE INVESTMENT MANAGEMENT INC

  • 10% Owner
  • * SEE REMARKS* SEE REMARKS* SEE REMARKS* SEE REMARKS* SEE REMARKS* SEE REMARKS
9,825,289 2017-08-31 0

SCHOEN ERIC SVP FINANCE & CAO

  • Officer
0 2017-03-23 0

RODDY PETER S

  • Director
181,334 2016-03-17 0

MUNROE DONALD G SVP BUSINESS DEVELOPMENT & CSO

  • Officer
0 2016-03-17 0

BAUZON HOLLY B VP MANAGED MARKETS

  • Officer
0 2015-07-06 0

MILLER LAURA ANN SVP SALES & CUST EXPERIENCE

  • Officer
0 2015-02-13 0

GOGGIN ROBERT ST LEGER

  • Director
243,685 2014-12-19 0

MCLAIN THOMAS H PRESIDENT & CEO

  • Officer
0 2014-03-27 0

VARMA ERIC

  • Director
23,000 2014-03-27 0

SACCO MARIAN E SVP SALES & MARKETING AND CCO

  • Officer
0 2014-03-27 0

FEINBERG LARRY N

ORACLE PARTNERS LP

ORACLE TEN FUND MASTER, LP

ORACLE ASSOCIATES LLC

ORACLE INVESTMENT MANAGEMENT INC

  • 10% Owner
  • SEE REMARKSSEE REMARKSSEE REMARKSSEE REMARKSSEE REMARKS
7,139,960 2013-12-19 0

WALLEN WILLIAM C

  • FORMER DIRECTOR
No longer subject to file 2013-12-12 0

HUEBNER BRUCE A

  • FORMER DIRECTOR
No longer subject to file 2013-12-12 0

CREECH WILLIAM B. VP, SALES AND MARKETING

  • Officer
30,137 2013-11-20 0

HAMILTON JOHN F

  • FORMER DIRECTOR
No longer subject to file 2013-03-21 0

PAGE GAIL S CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
0 2012-03-22 0

KOHLI ASHISH VP OF CORPORATE STRATEGY

  • Officer
13,500 2011-09-15 0

FUNG ERIC T S.V.P & C.S.O

  • Officer
52,471 2011-06-09 0

GARDINER SANDRA VP & CHIEF FINANCIAL OFFICER

  • Officer
24,000 2011-03-18 0

TRAN JOHN H. VP, FINANCE & CAO

  • Officer
0 2010-03-19 0

CONWAY KENNETH J

  • Director
0 2008-10-28 0

DALAL RAJEN

  • Director
0 2008-10-28 0

RATHMANN JAMES L

  • Director
0 2008-10-28 0

YOUNG JOHN A

  • Director
0 2008-10-28 0

TAYLOR RICHARD G INTERIM CFO

  • Officer
0 2008-08-26 0

PHRONESIS PARTNERS L P

WIGGINS JAMES

  • 10% Owner
982,222 2008-08-26 0

ZHOU QUN INTERIM CFO

  • Officer
0 2008-07-18 0

SHORTER SIMON C. VP, CORP BUSINESS DEVELOPMENT

  • Officer
0 2008-07-18 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

SCHREIBER DAVID - Director

2020-09-10 17:35:49 -0400 2020-09-08 S 50,000 $2.78 d 185,018 direct -8.7108 0.0 1.7422 5 -10.1045 3

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments